Overview

• Eli Lilly's Q1 revenue surged 45% year-over-year to $12.73 billion, exceeding Wall Street expectations.
• Sales of diabetes drug Mounjaro and weight-loss drug Zepbound reached $3.84 billion and $2.31 billion, respectively, driving U.S. revenue up by 49%.
• The company revised its full-year adjusted earnings forecast downward to $20.78–$22.28 per share, citing a $1.57 billion charge from acquiring a Scorpion Therapeutics cancer drug.
• Eli Lilly maintained its 2025 sales guidance of $58 billion to $61 billion, reflecting confidence in ongoing product demand.
• Shares fell 5% in premarket trading as investors reacted to the profit outlook cut despite robust Q1 results.